14 results

Shire Plc’s offices stand at the Citywest Business Campus in Dublin, Ireland. Photograph: Aidan Crawley / BLOOMBERG

Japan’s largest pharma group Takeda is considering a takeover bid for Irish rare disease specialist Shire. Takeda said Wednesday that its deliberatio(...)

Shire acquired Baxalta, which was a US rival, in a so-called mega-merger worth about $32 billion last year. Photograph: Aidan Crawley/Bloomberg

Earnings at Dublin-headquartered Shire Pharmaceuticals rose 14 per cent year on year during the first quarter of 2017 due to higher sales of rare dise(...)

Drugmaker Shire: earnings per American depositary share, excluding some costs, will grow to between $12.70 and $13.10 this year including results from Baxalta. Photograph: Suzanne Plunkett/Reuters

Drugmaker Shire said the $32 billion takeover of US rival Baxalta will boost earnings and sales this year, sending its stock surging to the highest le(...)

Ryanair: airline closed down nearly 1 per cent to €13.30 as the stock continued to be affected by lower oil prices. Photograph:  Alan Betson

European stocks fell for the fourth time in six days on Thursday led by declines in banks and carmakers. Already the worst performers among industry (...)

Pharmaceutical and biotech-led deals accounted for the lion’s share of transactions recorded here in 2015

Irish mergers and acquisitions (M&A) reached a seven-year high in 2015, according to new figures published by Experian. It says the overall numbe(...)

Shire CEO Flemming Ornskov is optimistic about the deal with Baxalta, but can these two very different companies fuel growth? Photograph: Aidan Crawley/Bloomberg

Flemming Ornskov had reason to be pleased yesterday. The Shire CEO’s six-month pursuit of rival Baxalta appears finally to have reached a successful c(...)

Shareholders will receive $18.00 in cash and 0.1482 Shire American depositary shares per Baxalta share

Dublin based Shire has agreed to buy Baxalta for about $32 billion (€29bn) to become the world’s biggest maker of so- called orphan drugs for rar(...)

 Shire has been focusing on acquiring companies with treatments for rare conditions. Photograph: Simon Dawson/Bloomberg

Shire, the pharmaceutical company based in Dublin, is in advanced talks to acquire Baxalta for about $32 billion (€29.5 billion) in cash and stock, ex(...)

A combination of Shire and Baxalta would add to the more than $600 billion in healthcare merger deals this year, which has been the busiest in the history of healthcare deal making

Dublin-based drug maker Shire has made a new acquisition offer for peer Baxalta International that is roughly in line with the latter’s valuation expe(...)

Pharmaceutical firm Shire said it was still pursuing its attempt to buy US company Baxalta as it posted a 11 percent rise in third-quarter earnings pe(...)

  • 1
  • 2
  • Next
  • Last »